NCT04575909

Brief Summary

This study is an investigation of a behavioral speech and language treatment for emotional prosody recognition and production deficits in subacute right hemisphere stroke.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Feb 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2020

Completed
17 days until next milestone

First Posted

Study publicly available on registry

October 5, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

February 1, 2021

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 19, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 19, 2024

Completed
Last Updated

March 20, 2024

Status Verified

March 1, 2024

Enrollment Period

3.1 years

First QC Date

September 18, 2020

Last Update Submit

March 19, 2024

Conditions

Keywords

ProsodyEmotionStrokeSpeech therapy

Outcome Measures

Primary Outcomes (6)

  • Change in accuracy on affective prosody expression following aprosodia intervention compared to spontaneous recovery

    Change in accuracy of participants' ability to express affective prosody on sentence lists (list score range 0-45), with increasing accuracy indicating better outcome.

    Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention

  • Change in accuracy on affective prosody recognition following aprosodia intervention compared to spontaneous recovery

    Change in accuracy of participants' ability to express affective prosody on sentence lists (list score range 0-45), with increasing accuracy indicating better outcome.

    Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention

  • Change in accuracy on standardized contextual measures of affective prosody expression

    Change in accuracy on the Montreal Evaluation of Communication (score range 0-18), with increasing score indicating better outcome.

    Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention

  • Change in accuracy on standardized contextualized measures of affective prosody recognition

    Change in accuracy on The Awareness of Social Inference Test (score range 0-24, with increasing score indicating better outcome.

    1 week after Phase I Intervention, 1 week after Phase II Intervention

  • Change in resting state functional connectivity

    Differences in resting state functional connectivity patterns within prosody-specific regions of interest and left homologues (connectivity association range 0-0.99), with increasing association values indicating stronger connectivity

    Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention

  • Behavioral and neurological predictors of aprosodia intervention outcomes

    Scores on baseline cognitive-linguistic assessments and percent damage to lesioned regions of interest, larger beta coefficients indicating a stronger relationship between predictor (baseline behavioral and neurological data) and predicted (prosody accuracy) variables.

    Baseline, 1 week after Phase I or Phase II Intervention

Secondary Outcomes (1)

  • Change in standardized acoustic features (rate, frequency, intensity, rhythm), on standardized measures of prosody expression

    Baseline, 1 week after Phase I Intervention, 1 week after Phase II Intervention

Study Arms (5)

Explicit Expressive Prosody Intervention

EXPERIMENTAL

Explicit cues will be provided to help participants improve expression of targeted affective prosody.

Behavioral: Aprosodia Intervention

Implicit Expressive Prosody Intervention

EXPERIMENTAL

Implicit cues will be provided to help participants improve expression of targeted affective prosody.

Behavioral: Aprosodia Intervention

Explicit Receptive Prosody Intervention

EXPERIMENTAL

Explicit cues will be provided to help participants improve recognition of targeted affective prosody.

Behavioral: Aprosodia Intervention

Implicit Receptive Prosody Intervention

EXPERIMENTAL

Implicit cues will be provided to help participants improve recognition of targeted affective prosody.

Behavioral: Aprosodia Intervention

No-Intervention

ACTIVE COMPARATOR

Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention \[if relevant\]), hobbies, and other similar topics.

Behavioral: No-Intervention

Interventions

Intervention will focus on improving participants' use and understanding of emotional prosody using implicit and explicit cues, biofeedback, modeling, and feedback.

Explicit Expressive Prosody InterventionExplicit Receptive Prosody InterventionImplicit Expressive Prosody InterventionImplicit Receptive Prosody Intervention
No-InterventionBEHAVIORAL

Sessions will comprise conversation about current events, recovery progress (including speech therapy goals targeted in outside intervention \[if relevant\]), hobbies, and other similar topics.

No-Intervention

Eligibility Criteria

Age18 Years - 89 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ischemic stroke to the right cerebral hemisphere
  • No history of other significant neurological disease or injury affecting the brain (excluding prior lacunar stroke, asymptomatic stroke, or TIA)
  • Proficient speaker of English prior to stroke per self-report
  • Capable of providing informed consent or indicating another to provide informed consent
  • Ages 18-89
  • Demonstration of receptive and/or expressive aprosodia on standardized measures of aprosodia
  • Does not have severe cognitive impairment (MoCA \> 9)
  • Is not severely depressed (PHQ-9 \< 20)
  • Does not have more than mild motor speech impairment (ASRS \< 16 and Dysarthria severity \< 3)
  • Normal or corrected-to-normal hearing and vision via screening tasks and self-report
  • Medically stable
  • Not taking any medications that may interfere with prosody processing
  • Participation in speech therapy not targeting aprosodia

You may not qualify if:

  • Ischemic stroke outside the right hemisphere or primary hemorrhagic stroke in the right hemisphere
  • History of symptomatic stroke or significant neurological disease or injury affecting the brain
  • No proficiency in English based on self-report
  • Unable to provide informed consent or to indicate another to provide informed consent
  • Children \< 18 and adults 90+ years
  • No demonstration of expressive or receptive aprosodia
  • Severe cognitive-linguistic impairment (MoCA \< 16)
  • Severe depression (PHQ-9 \> 19)
  • More than mild motor speech impairment (ASRS \> 15 + Dysarthria severity \< 2)
  • Uncorrected hearing/vision loss via screening tasks and self-report
  • Not medically stable
  • Reported medication use that may interfere with prosody processing
  • Participating in outside speech therapy targeting aprosodia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Johns Hopkins School of Medicine

Baltimore, Maryland, 21287, United States

Location

MeSH Terms

Conditions

StrokeCommunication Disorders

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesNeurobehavioral ManifestationsNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsNeurodevelopmental DisordersMental Disorders

Study Officials

  • Argye E Hillis, MD, MA

    Johns Hopkins University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Key personnel will be blinded to participant testing timepoint by having separate personnel administer treatment and assessments for each participant.
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: A crossover trial design with randomized order of intervention (REACT/no-intervention, no-intervention/REACT). Half of participants will be randomly assigned to REACT in Phase I, and the other half will be randomly assigned to start with no-intervention in Phase I. In Phase II, participants will receive the alternative intervention not received during Phase I.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 18, 2020

First Posted

October 5, 2020

Study Start

February 1, 2021

Primary Completion

March 19, 2024

Study Completion

March 19, 2024

Last Updated

March 20, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations